Significance of Worst Pattern of Invasion-5 in Early-Stage Oral Cavity Squamous Cell Carcinoma.


Journal

Head and neck pathology
ISSN: 1936-0568
Titre abrégé: Head Neck Pathol
Pays: United States
ID NLM: 101304010

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 15 05 2023
accepted: 05 07 2023
medline: 22 9 2023
pubmed: 24 7 2023
entrez: 24 7 2023
Statut: ppublish

Résumé

There is an ongoing need to identify pathologic prognosticators in early-stage oral cavity squamous cell carcinoma (OCSCC) to aid selection of patients who may benefit from adjuvant treatment. The objective of this study was to evaluate the prognostic ability of worst pattern of invasion-5 (WPOI-5) defined by the presence of satellite nodules, extratumoural perineural invasion (PNI) and/or extratumoural lymphovascular space invasion (LVI) in low-stage, node negative OCSCC. This was a retrospective study of 160 patients with T1/T2N0 tumours staged using TNM7 treated surgically. Histology of the primary tumour was re-reviewed as appropriate to assess for the presence of WPOI-5 parameters. Univariate and multivariate analysis assessing impact of pathological features on survival outcomes was performed. On univariate analysis, WPOI-5 and its 3 constituent components of satellite nodules, extratumoural PNI and extratumoural LVI were all significantly associated with disease-specific survival (DSS) and overall survival (OS). On multivariate analysis, satellite nodules (odds ratio 6.61, 95% CI 2.83-15.44, p < 0.0001) and extratumoural LVI (odds ratio 9.97, 95% CI 2.19-45.35, p = 0.003) were independently associated with OS. Postoperative radiotherapy (odds ratio 0.40, 95% CI 0.19-0.87, p = 0.02) and non-tongue subsite (odds ratio 3.03, 95% CI 1.70-5.39, p = 0.0002) were also significantly associated with OS on multivariate analysis. Satellite nodules and extratumoural LVI correlated significantly with survival outcomes in our early-stage OSCC cohort. Further study is required to investigate the benefit of adjuvant treatment in these cases and to ascertain if WPOI-5 parameters including satellite nodules should be mandatory reporting data elements.

Sections du résumé

BACKGROUND BACKGROUND
There is an ongoing need to identify pathologic prognosticators in early-stage oral cavity squamous cell carcinoma (OCSCC) to aid selection of patients who may benefit from adjuvant treatment. The objective of this study was to evaluate the prognostic ability of worst pattern of invasion-5 (WPOI-5) defined by the presence of satellite nodules, extratumoural perineural invasion (PNI) and/or extratumoural lymphovascular space invasion (LVI) in low-stage, node negative OCSCC.
METHODS METHODS
This was a retrospective study of 160 patients with T1/T2N0 tumours staged using TNM7 treated surgically. Histology of the primary tumour was re-reviewed as appropriate to assess for the presence of WPOI-5 parameters. Univariate and multivariate analysis assessing impact of pathological features on survival outcomes was performed.
RESULTS RESULTS
On univariate analysis, WPOI-5 and its 3 constituent components of satellite nodules, extratumoural PNI and extratumoural LVI were all significantly associated with disease-specific survival (DSS) and overall survival (OS). On multivariate analysis, satellite nodules (odds ratio 6.61, 95% CI 2.83-15.44, p < 0.0001) and extratumoural LVI (odds ratio 9.97, 95% CI 2.19-45.35, p = 0.003) were independently associated with OS. Postoperative radiotherapy (odds ratio 0.40, 95% CI 0.19-0.87, p = 0.02) and non-tongue subsite (odds ratio 3.03, 95% CI 1.70-5.39, p = 0.0002) were also significantly associated with OS on multivariate analysis.
CONCLUSION CONCLUSIONS
Satellite nodules and extratumoural LVI correlated significantly with survival outcomes in our early-stage OSCC cohort. Further study is required to investigate the benefit of adjuvant treatment in these cases and to ascertain if WPOI-5 parameters including satellite nodules should be mandatory reporting data elements.

Identifiants

pubmed: 37486537
doi: 10.1007/s12105-023-01571-9
pii: 10.1007/s12105-023-01571-9
pmc: PMC10513981
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

679-687

Informations de copyright

© 2023. The Author(s).

Références

CA Cancer J Clin. 2017 Mar;67(2):122-137
pubmed: 28128848
Oral Oncol. 2010 Jan;46(1):49-55
pubmed: 20005769
J Clin Diagn Res. 2013 Nov;7(11):2559-62
pubmed: 24392400
Head Neck. 2003 Nov;25(11):937-45
pubmed: 14603454
Oral Oncol. 2019 Aug;95:65-73
pubmed: 31345396
J Oral Maxillofac Surg. 2013 Apr;71(4):775-85
pubmed: 23265849
Br J Oral Maxillofac Surg. 2019 Jun;57(5):454-459
pubmed: 31031061
Head Neck Pathol. 2013 Sep;7(3):211-23
pubmed: 23250819
Laryngoscope. 2002 Apr;112(4):616-25
pubmed: 12150512
Head Neck Pathol. 2016 Dec;10(4):451-464
pubmed: 27140176
Oral Oncol. 2002 Jul;38(5):500-3
pubmed: 12110346
Clin Otolaryngol. 2020 Jan;45(1):99-105
pubmed: 31677332
Oral Oncol. 2009 Jan;45(1):10-5
pubmed: 18620889
Am J Surg Pathol. 2010 May;34(5):676-88
pubmed: 20414102
J Surg Oncol. 2009 Feb 1;99(2):104-8
pubmed: 19034903
J Natl Cancer Inst. 2002 Jul 17;94(14):1066-70
pubmed: 12122097
Am J Otolaryngol. 2012 Mar-Apr;33(2):212-5
pubmed: 22177613
Acta Otolaryngol. 2014 Apr;134(4):416-24
pubmed: 24628337
Histopathology. 2016 Dec;69(6):914-920
pubmed: 27271979
Expert Rev Anticancer Ther. 2006 Mar;6(3):405-17
pubmed: 16503857
Head Neck. 2018 Aug;40(8):1780-1787
pubmed: 29707840
Head Neck Pathol. 2021 Sep;15(3):935-944
pubmed: 33788136
Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 Mar;131(3):319-328.e1
pubmed: 33309267
Int J Oral Maxillofac Surg. 2022 Jan;51(1):1-9
pubmed: 33814227
Oral Oncol. 2002 Jun;38(4):394-7
pubmed: 12076706
Ear Nose Throat J. 2019 Aug;98(7):E112-E119
pubmed: 31072197
Otolaryngol Head Neck Surg. 2013 Dec;149(6):893-9
pubmed: 24154744
Virchows Arch. 2021 Sep;479(3):597-606
pubmed: 33661329
Head Neck. 2014 Jun;36(6):811-8
pubmed: 23696499
Int J Epidemiol. 2010 Apr;39(2):598-610
pubmed: 20142331
Arch Otolaryngol Head Neck Surg. 1998 Jun;124(6):637-40
pubmed: 9639472
Curr Opin Otolaryngol Head Neck Surg. 2007 Apr;15(2):74-81
pubmed: 17413406
Oral Oncol. 2010 Aug;46(8):577-85
pubmed: 20400361
Head Neck. 2013 Sep;35(9):1362-70
pubmed: 22941934
Am J Surg. 2000 Aug;180(2):139-43
pubmed: 11044531
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):284-90
pubmed: 21075550
Am J Surg Pathol. 2005 Feb;29(2):167-78
pubmed: 15644773
Int J Oral Maxillofac Surg. 2015 Jan;44(1):23-8
pubmed: 25457832
Head Neck. 2011 Jul;33(7):928-34
pubmed: 21674667
JAMA Otolaryngol Head Neck Surg. 2014 Dec;140(12):1138-48
pubmed: 25075712

Auteurs

Shima Mohamed (S)

Department of Pathology, Cork University Hospital, Wilton, Cork, T12 DC4A, Ireland.
St James's Hospital, Dublin, Ireland.

Hadeel Jawad (H)

Department of Pathology, Cork University Hospital, Wilton, Cork, T12 DC4A, Ireland.
Black Country Pathology Services, NHS, Wolverhampton, UK.

Ryan O' Sullivan (RO)

Department of Otolaryngology, South Infirmary Victoria University Hospital, Cork, Ireland.

Deirdre Callanan (D)

Department of Otolaryngology, South Infirmary Victoria University Hospital, Cork, Ireland.
ENTO Research Unit, College of Medicine and Health, University College Cork, Cork, Ireland.

Patrick Sheahan (P)

Department of Otolaryngology, South Infirmary Victoria University Hospital, Cork, Ireland.
Department of Surgery, University College, Cork, Ireland.
ENTO Research Unit, College of Medicine and Health, University College Cork, Cork, Ireland.

Linda Feeley (L)

Department of Pathology, Cork University Hospital, Wilton, Cork, T12 DC4A, Ireland. Linda.feeley@hse.ie.
ENTO Research Unit, College of Medicine and Health, University College Cork, Cork, Ireland. Linda.feeley@hse.ie.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH